Call for experts: International survey on radioligand therapy and theranostics
Radioligand therapy (RLT) and theranostics are rapidly gaining recognition as transformative approaches in cancer management, offering highly targeted treatment options for patients. To understand and prepare for this evolving landscape, the OECD Nuclear Energy Agency (NEA) is conducting an international survey to gather expert insights on the current status of radioligand therapy (RLT) and its integration into cancer care, while also forecasting future demand.
Dr. Jochen Walz (FR), who serves as the EAU’s contact person to the European Association of Nuclear Medicine (EANM) shares insights on this research and highlights the importance of urologists participating in these surveys to support the implementation of international strategies for patient access to RLT. Recently, the EAU and the EANM signed a Memorandum of Understanding (MoU) to strengthen cross-disciplinary collaboration in cancer care.
According to Dr. Walz, the NEA project has four main objectives:
- Estimate the number of eligible patients for RLT over the next 10-15 years.
- Assess healthcare system readiness such as infrastructure, workforce, regulations, and funding challenges.
- Secure the supply of key therapeutic radioisotopes, such as Lutetium-177 and Actinium-225.
- Develop evidence-based recommendations to the 38 OECD member countries to ensure timely and equitable access to RLT and theranostics.
Dr. Walz emphasises why this research matters: “Such projects raise awareness about RLT by addressing the most pressing questions. They also provide a cross-sectional view of the situation in many countries, highlighting availability, bottlenecks, and opportunities for improvement.”
How to participate in the surveys
Nuclear Energy Agency (NEA) - Survey: Current status of radioligand therapy and patient eligibility
Survey 1 – Current status of RLT and RLI
Current status of RLT
This survey collects information on the clinical use, therapeutic efficacy, innovation pipelines, and healthcare system readiness for delivering RLT and Radioligand Imaging (RLI).
Surveys 2 & 3 – Patient eligibility for RLT
Patient eligibility for RLT part1
Patient eligibility for RLT part2
These surveys aim to estimate the number of patients eligible for RLT, including those eligible under emerging radiopharmaceutical approaches, to help forecast future demand.
Responses are invited from experts on behalf of their country, region, or institution. Even approximate data, or qualitative assessments are welcome, as the NEA seeks to build as comprehensive a picture as possible. The results will contribute to an official OECD/NEA publication, currently planned for release in late-2026.
Deadline for survey submission is 31 October 2025. For more information, you can contact via the OECD NEA.
Suggested for you
See allThere are no news articles related to this page right now. See all news articles